Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5652W HIGH $21.72
Volume
104.86 K
Value Traded
30.32 K
Short % Float
22.16%
+18.3%Week
-47.48%1 Month
-38.93%3 Month
-43.38%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.93 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
1.58 M
Float Shares
720.00 K
Insiders
54.32%
Institutions
0.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BMGL Catalyst Timeline
Dated clinical, regulatory and corporate events for Basel Medical Group Ltd Ordinary Shares
Past FDA Catalysts and PDUFA Decisions
How BMGL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Basel Medical Group Ltd is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BMGL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BMGL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BMGL for Q2 2026. | ||||
BMGL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BMGL ranks across every disease it competes in
Competitive Position is a premium feature
See how BMGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBMGL News
-BMGL
Oct 9, 2026▲ +2.5%today
Basel Medical Group Ltd (BMGL) Closes Registered Direct Offering
Basel Medical Group Ltd has successfully closed a registered direct offering, raising approximately $7.98 million. The funds will be allocated for general working capital and potential mergers and acquisitions. The offering included 6,000,000 units, each consisting of an ordinary share and a common warrant. The company has agreed to a 180-day lock-up period for certain shareholders and executives.
Read more →-BMGL
Jul 10, 2026BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement
Basel Medical Group Ltd (BMGL) has announced that it has regained compliance with Nasdaq's minimum bid price rule after its shares maintained a closing price of $1.00 or greater for the last 10 consecutive business days. This follows a notification from Nasdaq on January 22, 2026, regarding a previous failure to meet the minimum bid price requirement. The company is well-positioned for growth in the private healthcare sector in Singapore and Southeast Asia.
Read more →-BMGL
Jun 10, 2026▼ -8%on this news
BMGL to Effect Reverse Share Split on June 22, 2026
Basel Medical Group Ltd (BMGL) announced a 1-for-12 reverse share split effective June 22, 2026, to comply with Nasdaq's minimum bid price requirement. This consolidation will reduce the number of outstanding shares from approximately 18.8 million to about 1.6 million. The split will occur automatically without requiring action from shareholders.
Read more →-BMGL
Jun 10, 2026▼ -8%on this news
Basel to Effect Reverse Share Split on June 22, 2026
Basel Medical Group Ltd (BMGL) has announced a reverse share split effective June 22, 2026, at a 1-for-12 ratio to comply with Nasdaq Marketplace Rule. This consolidation will automatically convert every 12 ordinary shares into one, reducing the total from approximately 18.8 million to about 1.6 million shares. No shareholder approval is required for this action, which is designed to help maintain a minimum bid price of $1 per share post-split. The adjusted shares will continue trading under the same Nasdaq symbol, BMGL, although the CUSIP number will change.
Read more →-BMGL
Jun 10, 2026▼ -8%on this news
QingSong Health Corp (2661.HK) and Basel Medical Sign Strategic Cooperation Memorandum to Explore AI Healthcare Services in Southeast Asia
QingSong Health Corp and Basel Medical Group have signed a Memorandum of Strategic Cooperation to explore AI healthcare services in Southeast Asia. The collaboration aims to enhance existing healthcare services using AI technology and to develop cross-border healthcare solutions. This partnership will leverage QingSong's AI capabilities and Basel's established healthcare network in the region.
Read more →-BMGL
Mar 24, 2026▼ -7.3%on this news· ran to -22% by day 3
Compliance With Nasdaq Periodic Filing Requirement
Basel Medical Group Ltd (BMGL) has announced its compliance with Nasdaq's periodic filing requirement after submitting its amended annual report for the fiscal year 2025. The company received confirmation from Nasdaq that the previous deficiency related to the Periodic Filing Rule has been resolved. Basel Medical is a Singapore-based provider of various medical services and is poised for growth in the healthcare industry.
Read more →-BMGL
Jan 23, 2026Receipt of Delinquency Notification from Nasdaq Singapore
Basel Medical Group Ltd (BMGL) has received a notification from Nasdaq indicating that it no longer meets the minimum bid price requirement of $1 per share based on the closing bid price over the past 30 consecutive business days. The company has a compliance period of 180 calendar days to rectify this situation, potentially through a reverse stock split. If compliance is not achieved within this timeframe, BMGL may be subject to further actions by Nasdaq, although trading of the company's shares is currently unaffected. The company is already working on a plan to address this compliance issue.
Read more →-BMGL
Dec 1, 2025Receipt of Delinquency Notification from Nasdaq
Basel Medical Group Ltd (BMGL) has received a delinquency notification from Nasdaq due to an incomplete annual report for the fiscal year ended June 30, 2025. This notification indicates that the report lacked the required opinion from its auditor regarding the company's financial statements. The company has 60 days to submit a compliance plan, which, if accepted, may grant them an additional 180 days to rectify the issue. Meanwhile, trading of BMGL shares on Nasdaq remains unaffected by this compliance issue.
Read more →-BMGL
Jul 17, 2025July 17, 2025 (GLOBE NEWSWIRE) - Basel Medical Group Ltd (Nasdaq: BMGL or the "Company"), today announced that it is putting on hold on the acquisition of BTC digital asset. After thorough discussions, Basel and the consortium of Bitcoin (BTC)
Basel Medical Group Ltd has announced a halt on its acquisition of BTC digital assets amid ongoing regulatory reviews by US authorities. Both parties involved mutually agreed to defer the transaction until there is greater clarity regarding the regulatory landscape. Despite this setback, Basel Medical Group remains well-integrated within Singapore's healthcare sector, leveraging its established operations and industry relationships for future growth. The company will continue monitoring developments to reassess the acquisition opportunity.
Read more →-BMGL
Jun 26, 2025▼ -12.6%on this news
Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising
Basel Medical Group Ltd has announced a waiver of the lock-up provision from its underwriting agreement, allowing for potential fundraising through the issuance of new securities. This is seen as a significant opportunity as the company evaluates its capital requirements. The firm, based in Singapore, is positioned in a growing healthcare market, especially after its recent acquisition of Bethesda Medical, enhancing its service capabilities. However, the company also notes the uncertainty surrounding these fundraising efforts.
Read more →-BMGL
Jun 18, 2025Basel Medical Group Ltd and its Subsidiaries Unaudited Consolidated Financial Statements For the financial period ended
Basel Medical Group Ltd has released its unaudited consolidated financial statements for the financial period ending December 31, 2024. The company experienced a substantial loss before tax of USD 231,768 and a total comprehensive loss of USD 232,231 during this period. Revenue decreased slightly compared to the previous year, while expenses related to employee benefits and other operating costs saw notable increases. This report indicates ongoing financial challenges for the company amid changes in ownership structure.
Read more →-BMGL
May 29, 2025Basel Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility May 29, 2025 (GLOBE NEWSWIRE) - Basel Medical Group Ltd (Nasdaq: BMGL or the "Company"), today reaffirmed the strength
Basel Medical Group Ltd (BMGL) has reaffirmed its strong financial position amid recent market volatility affecting its share price. CEO Dr. Darren Chhoa emphasized that the company's fundamentals remain robust, highlighted by operational success and new contracts being secured in the supply chain. BMGL aims to continue its growth trajectory through strategic acquisitions and a solid commitment to shareholder value, leveraging its established presence in the private healthcare market in Singapore and beyond. The company remains optimistic about future growth opportunities driven by various demographic and economic factors.
Read more →-BMGL
May 20, 2025▼ -6.6%on this news· ran to -36% by day 3
Basel Medical Group Subsidiary Awarded S$375 Million Contract to Supply Healthcare Products; Group to Enhance AI-Powered Healthcare Supply Chain Capabilities Singapore
Basel Medical Group Ltd has secured a S$375 million contract with Pancare Technology International to supply essential healthcare products in the Asia-Pacific region over the next five years. This contract reflects the company's dedication to delivering high-quality medical solutions and enhancing its presence in the healthcare sector. Additionally, the group plans to leverage AI-powered technologies to improve supply chain operations, optimizing logistics and ensuring timely deliveries. The CEO expressed confidence in the company’s capabilities and commitment to transforming healthcare delivery through innovation.
Read more →-BMGL
May 16, 2025▼ -9.9%on this news· ran to -29% by day 3shared move
Basel Medical Group Ltd Kicks Off US$ 1.0 Billion Bitcoin (BTC) Acquisition Strategy Move Singapore
Basel Medical Group Ltd (BMGL) has initiated exclusive negotiations for a US$1 billion Bitcoin acquisition strategy to diversify its treasury reserves while focusing on expanding medical services. This financial initiative aims to strengthen BMGL's balance sheet and support growth across Asia's healthcare markets. The CEO highlighted that such a move would provide unmatched financial flexibility for future mergers and acquisitions, ensuring BMGL is well-capitalized in emerging market landscapes. The company anticipates finalizing the terms of this significant transaction within the current quarter, pending regulatory approvals.
Read more →-BMGL
Apr 30, 2025Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
Basel Medical Group Ltd has successfully acquired Bethesda Medical Pte. Ltd., a prominent healthcare provider in Singapore, marking a strategic expansion in the Southeast Asian healthcare sector. This acquisition aims to enhance patient care and improve operational efficiencies through a closer partnership between the two organizations. Basel Medical Group, known for its orthopedic services, expects to create a seamless referral system that will broaden service offerings and strengthen its position in the market. The integration is predicted to drive better clinical outcomes and capitalize on growth opportunities in the region's evolving healthcare landscape.
Read more →-BMGL
Apr 11, 2025Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia Singapore
Basel Medical Group Ltd has announced a definitive agreement to acquire Bethesda Medical Pte. Ltd., a prominent healthcare provider in Singapore. This acquisition aims to strengthen Basel's presence in the Singapore and Southeast Asian healthcare markets by integrating diagnostic imaging and outpatient services with their existing offerings. The partnership is projected to improve patient access to specialized treatments and enhance clinical outcomes through a seamless referral system. Completion of the acquisition is anticipated by April 30, 2025, pending customary closing conditions.
Read more →-BMGL
Mar 19, 2025Basel Medical Group Ltd Announces Exercise of Overallotment Option
Basel Medical Group Ltd has successfully exercised its overallotment option, allowing the purchase of an additional 330,750 ordinary shares at $4.00 per share. This move has generated gross proceeds of $1,323,000, bringing the total capital raised from its initial public offering to $10,143,000. The company aims to utilize these funds for mergers and acquisitions, expanding clinic operations, and covering daily operational costs. Trading of the company's shares began on February 25, 2025, under the ticker symbol BMGL.
Read more →-BMGL
Mar 3, 2025Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public
Basel Medical Group Ltd has successfully closed its initial public offering, raising US$8,820,000 by offering 2,205,000 ordinary shares at US$4.00 each. The shares began trading on the Nasdaq Capital Market under the ticker BMGL on February 25, 2025. The funds raised will be allocated for potential mergers and acquisitions, business expansion, and operational needs. The company aims to enhance its service capabilities and achieve growth amid the increasing demand for healthcare services in Singapore.
Read more →-BMGL
Feb 25, 2025Basel Medical Group Ltd Prices US$8,820,000 Initial Public Offering
Basel Medical Group Ltd has priced its initial public offering at US$4.00 per share, looking to raise a total of US$8,820,000. The offer consists of 2,205,000 shares and is set to commence trading on the Nasdaq Capital Market under the ticker BMGL. Proceeds will primarily fund business expansion efforts, including additional clinic space and enhanced capabilities. The offering is expected to close on February 26, 2025, pending customary closing conditions.
Read more →About Basel Medical Group Ltd Ordinary Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next BMGL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime